Advertisement

Neuroendocrine Cancer of the Prostate

  • Noémi Kránitz
  • Zsolt Szepesváry
  • Károly Kocsis
  • Tamás KullmannEmail author
Original Article
  • 14 Downloads

Abstract

Neuroendocrine cancer of the prostate is considered to be a rare entity with bad prognosis and limited therapeutic options. We performed a prospective analysis of the patients treated in our hospital for prostate cancer between 1st January 2015 and 31rd December 2018. Neuroendocrine phenomena were tested by immunohistochemistry and laboratory chemistry on the request of the clinicians in the cases when a positive diagnosis was suspected. Clinical tableaux of high suspicion of neuroendocrine cancer included radiological progression of a metastatic disease without PSA rise, relatively extended metastatic disease associated to a low PSA, disease with non-pulmonary visceral metastases. 10 patients were diagnosed with neuroendocrine tumour out of 521 prostate cancers. Half of the patients had a survival over a year. 3 patients received 3 lines of efficacious palliative chemotherapy. 1 patient underwent prostatectomy after neoadjuvant chemotherapy for a localised disease. The incidence of neuroendocrine tumours among prostate cancer patients was higher than expected. Some of the patients had a relatively good outcome.

Keywords

Neuroendocrine Prostate cancer Immunohistochemistry Serum marker Platinum 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors have no conflict of interest in connection with the publication of this article.

References

  1. 1.
    Honn KV, Aref A, Chen YQ et al (1996) Prostate cancer - old problems and new approaches. (Part II. Diagnostic and prognostic markers, Pathology and Biological Aspects). Pathol Oncol Res 2:191–211CrossRefGoogle Scholar
  2. 2.
    Parimi V, Goyal R, Poropatich K, Yang XJ (2014) Neuroendocrine differenciation of prostate cancer: a review (2014). Am J Clin Exp Urol 2:273–285Google Scholar
  3. 3.
    Li J, Wang Z (2016) The pathology of unusual subtypes of prostate cancer. Chin J Cancer Res 28:130–143Google Scholar
  4. 4.
    Zaffuto E, Pompe R, Zanaty M et al (2017) Contemporary incidence and cancer control outcomes of primary neuroendocrine prostate cancer: a SEER database analysis. Clin Genitourin Cancer 15:e793–e800CrossRefGoogle Scholar
  5. 5.
    Kishore K, Rafeeq A, Chime C et al (2018) Poorly differentiated small-cell-type neuroendocrine carcinoma of the prostate: a case report and literature review. Case Rep Oncol 11:676–681CrossRefGoogle Scholar
  6. 6.
    Palmgren JS, Karavadia SS, Wakefield MR (2007) Unusual and underappreciated: small cell cancer of the prostate. Semin Oncol 34:22–29CrossRefGoogle Scholar
  7. 7.
    Beltran H, Oromendia C, Danila DC et al (2019) A phase II trial of the Aurora kinase a inhibitor alisertib for patients with castration-resistant and neuroendocrine prostate cancer: efficacy and biomarkers. Clin Cancer Res 25:43–51CrossRefGoogle Scholar
  8. 8.
    Monn MF, Cheng L (2016) Emerging trend in the evaluationand management of small cell prostate cancer: a clinical and molecular perspective. Expert Rev Anticancer Ther 16:1029–1037CrossRefGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2019

Authors and Affiliations

  • Noémi Kránitz
    • 1
  • Zsolt Szepesváry
    • 2
  • Károly Kocsis
    • 3
  • Tamás Kullmann
    • 3
    Email author
  1. 1.Department of PathologyPetz Aladár HospitalGyőrHungary
  2. 2.Department of UrologyPetz Aladár HospitalGyőrHungary
  3. 3.Department of OncoradiologyPetz Aladár HospitalGyőrHungary

Personalised recommendations